Abstract Details

Title Markers of Vitamin B12 Status in Relation to Cerebrospinal Fluid Biomarkers and Cognitive Performance

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P5 - Poster Session 5 (8:00 AM-9:00 AM)

Poster/Presentation
Number 10-006

Objective

To investigate the associations of vitamin B12 related markers (vitamin B12, holotranscobalamin (HoloTC), homocysteine (tHcy), and methylmalonic acid (MMA)) with CSF total tau, Amyloid-β 42 (Aβ42) and cognitive performance.

Background

The association between markers of vitamin B12 status and cerebrospinal fluid (CSF) biomarkers of Alzheimer’s type dementia which precede cognitive impairment has been investigated by only a few small studies and the results have been inconsistent.

Design/Methods Data included 462 patients aged 40-94 years referred to the Memory Clinic at the Ulm University Hospital, Ulm, Germany between December 2009 and August 2015. Vitamin B12 and HoloTC were measured via chemiluminescence microparticle immunoassay, tHcy via chemiluminescence immunoassay and MMA via liquid chromatography mass specterometry. CERAD battery was used to examine the cognitive status, and different domains were derived. Regression models were used to investigate the associations.

Results

After adjusting for age, sex, creatinine levels and APOEε4 status, higher values of vitamin B12 and lower values of MMA were associated with lower concentrations of CSF total-tau: the odds ratios (ORs) (95% confidence intervals (CI)) in a binary logistic regression analysis investigating the associations with total tau cut-off of 400 pg/ml were 0.39 (0.15 - 0.99) and 5.60 (1.93 - 16.26) for the highest quartile of B12 and MMA compared to the lowest, respectively. Furthermore, HoloTC, MMA, and tHcy were associated with several cognitive domains such as episodic memory and executive functioning. No relationships were found with Aβ42.

Conclusions Vitamin B12 and its related markers may be independent predictors of CSF biomarkers of Alzheimer’s disease and cognitive status. Randomized controlled trials are needed to determine the importance of vitamin B12 supplementation on slowing structural brain changes and cognitive decline in older adults.

Authors/Disclosures
Babak Hooshmand, MD, PhD (Aging Research Center, Karolinska Institute) PRESENTER	Dr. Hooshmand has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Hayrettin Tumani, MD (Universitatsklinik Ulm RKU)	Dr. Tumani has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer. Dr. Tumani has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Tumani has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Genzyme. Dr. Tumani has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. Tumani has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Tumani has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Tumani has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Tumani has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva.
Miia Kivipelto, MD	No disclosure on file
Christine A. Von Arnim, MD (UNIVERSITY MEDICAL CENTER GOETTINGEN)	No disclosure on file

�鶹��ýӳ��

�鶹��ýӳ��

Abstract Details